 |
|
|
| |
Treatment with Telaprevir/Peg-IFN/RBV After 14-day Telaprevir Exposure in Phase I Studies: Results from the Phase IIIB C219 Rollover Study
|
| |
| |
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Christoph Sarrazin,1 Henk W Reesink,2 Stefan Zeuzem,1 Inge Dierynck,3 Don Luo,4 James Witek,4 Gaston Picchio,4 Sandra De Meyer3
1Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 2Academic Medical Center, Amsterdam, The Netherlands; 3Janssen Infectious Diseases, Beerse, Belgium; 4Janssen Research and Development LLC, NJ, USA
|
| |
|
|
|
|
|
